Hepatitis B virus antigen peptide and application thereof

By synthesizing antigenic peptides based on the hepatitis B virus-encoded protein and HLA haplotype, T cells are activated, and the problem of poor treatment effect of HBV infection in liver cancer in the prior art was solved, individualized immunotherapy was achieved, and the normalization of the patient's immune treatment was significantly improved. The killing ability of HBV-infected cells provides standardized immunotherapy regimens for liver cancer.

CN119039403APending Publication Date: 2024-11-29CHENGDU LANGGU BIOTECHNOLOGY CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410863905.5
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2022-01-05
Publication Date
2024-11-29

AI Technical Summary

Technical Problem

The prior art is difficult to provide individualized effective antigenic peptides against hepatitis B virus (HBV), which leads to poor treatment of liver cancer caused by HBV infection, and lacks accurate immunotherapy plans for individuals with different HLA haplotypes.

Method used

Based on the amino acid sequence of the protein encoded by hepatitis B virus, combining human leukocyte antigen haplotypes in class I molecules of different major histocompatibility complexes, antigen peptides were synthesized using biological information prediction methods, and applied to immunotherapy drugs to activate Specific T cells to enhance the killing ability of HBV-infected liver cancer cells.

Benefits of technology

The activation of T cells through individualized antigen peptides has significantly improved the killing ability of HBV-infected liver cancer cells, verified its effectiveness in human experiments, filled the gap in individualized antigen peptides in liver cancer treatment, and provided standardized individualization HBV-related liver cancer immunotherapy regimen.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119039403A_ABST
    Figure CN119039403A_ABST
Patent Text Reader

Abstract

The invention relates to an antigen peptide aiming at hepatitis B virus, which is synthesized by combining human leukocyte antigen haplotypes in I-type molecules of different major histocompatibility complexes and using a biological information prediction method on the basis of an amino acid sequence of hepatitis B virus coding protein. The antigen peptide comprises at least one of amino acid sequences as shown in SEQ ID NO: 1-124. According to the antigen peptide disclosed by the invention, the individualized effectiveness of the antigen peptide is verified by utilizing an immune experiment in a human body experiment, so that the blank of the individualized antigen peptide in liver cancer treatment is filled up; the antigen peptide disclosed by the invention can be used for remarkably activating T cells specifically aiming at HBV (Hepatitis B Virus) of a human body and increasing the killing ability of the T cells on HBV-infected liver cancer cells, and the antigen peptide can be applied to standardized individualized HBV-related liver cancer immunotherapy through large-scale synthesis.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] This invention is a divisional application of the Chinese invention patent application with application number "202210011045.3", invention name "Antigenic peptide for hepatitis B virus and its application", and application date of January 5, 2022. Technical Field

[0002] The present invention relates to the technical field of immunotherapy drugs, and in particular to an antigen peptide targeting hepatitis B virus and application thereof. Background Art

[0003] Tumor immunotherapy is considered to be a new generation of tumor treatment methods after surgery, radiotherapy, chemotherapy and small molecule targeted therapy. It is different from previous traditional treatment methods in that immunotherapy changes the treatment method from direct killing of tumor cells by drugs to the enhancement of immune cells, and treats tumors by improving the patient's own anti-tumor immunity. Compared with traditional treatments, it has the advantages of precise killing, few side effects and long-lasting efficacy. In addition, the body's immune system has the characteristics of immune memory, so immunotherapy can help patients form memory immunity, which has significant advantages in preventing tumor recurrence and metastasis.

[0004] Hepatocellular carcinoma (HCC) ranks fifth among the most common tumors, with a wide range of regional differences, and an annual incidence of about 1 million worldwide. About 80% of liver cancers are related to hepatitis B virus infection (HBV). About 15%-40% of untreated infected people will develop cirrhosis, liver failure or liver cancer. In general, although the incidence of liver cancer in Chinese people is less than 20 per 100,000 per year, many patients are already in the advanced stage when they have symptoms, and the opportunity for resection is lost, so the median survival rate is less than half a year. A small number of patients have a 5-year survival rate of about 40% after the cancerous tissue of the liver is removed.

[0005] The HBV genome contains 3200 bases, including 4 open reading frames (ORFs) all located in the negative strand, namely S region, C region, P region, and X region. The S region is divided into three coding regions: pre-S1, pre-S2, and S, which encode the pre-S1 protein, pre-S2 protein, and HBsAg on the envelope, respectively. The pre-S protein has strong immunogenicity, and the hepatotropism of HBV is mainly mediated by the recognition between the pre-S protein and the hepatocyte receptor. The C region is divided into the pre-C gene and the C gene, encoding HBeAg and HBcAg. The protein encoded by the pre-C gene is processed and secreted outside the cell, which is HBeAg; the protein encoded by the C gene is HBcAg. The P region is the longest reading frame, encoding a large molecular alkaline polypeptide with a molecular weight of about 90KD and containing a variety of functional proteins. The X gene encodes the X protein, namely HBxAg. HBxAg has a transactivation effect, which can activate a variety of regulatory genes of HBV itself, other viruses, or cells, and promote the replication of HBV.

[0006] In order to find personalized antigenic peptides for HBV, it is necessary to predict the antigenicity of proteins and peptides expressed by HBV, synthesize potential antigenic peptides in vitro, and finally use high-concentration and high-intensity tumor vaccines to activate immune cells. Scientists have long been based on basic research in immunology, and research on T cell antigen recognition has made great progress. Studies have found that peptides (also known as antigen epitopes) formed after degradation of certain mutant proteins in tumors can be specifically recognized by major histocompatibility complex (MHC) molecules and form MHC-antigen peptide complexes. The complexes are then presented to the surface of cells and recognized by T cells as non-self components, so that T cells are activated into effector T cells to attack and eliminate tumor cells. The most critical step is the combination of MHC molecules and polypeptide molecules. The MHC molecules in the human body are also called human leukocyte antigens (HLA), which are mainly divided into MHC class I molecules and MHC class II molecules. The former are expressed by most cells and are mainly involved in the presentation of endogenous antigens; while the latter are mainly expressed by antigen-presenting cells and are mainly involved in the presentation of exogenous antigens. There are three genes encoding MHC I (HLA-A, HLA-B and HLA-C) and three genes encoding MHC II (HLA-DR, HLA-DQ, HLA-DP) in the human genome. These genes vary greatly. Currently, tens of thousands of different genotypes have been found, which are called HLA haplotypes. Each haplotype is named by international statistics. Different haplotypes generally have different affinities for the same polypeptide, that is, the ability to recognize it as an antigen. The stronger the affinity, the stronger the recognition ability. Since the antigenic peptides recognized by the major histocompatibility complex class I molecules are relatively short, the relevant research and analysis of the major histocompatibility complex-antigenic peptide complex is also more sufficient. So far, scientists in related fields have built multiple epitope databases and developed multiple software for predicting epitopes based on individualized HLA haplotypes for major histocompatibility complex class I molecules (such as NetMHCpan4.0, NetMHCpan-BA, NetMHCpan-EL, MHCFlurry, ANN, SMM or CombLib). The more different software simultaneously predicts an antigen peptide, the higher the accuracy of the antigen. Based on current research and analysis methods, it is possible to predict and design targeted antigen peptides for individualized treatment for different individualized targets. Summary of the invention

[0007] The purpose of the present invention is to provide an antigen peptide against hepatitis B virus and its application in view of the deficiencies in the prior art.

[0008] To achieve the above object, the technical solution adopted by the present invention is:

[0009] The first aspect of the present invention is to provide an antigenic peptide against hepatitis B virus, based on the amino acid sequence of the protein encoded by hepatitis B virus, combined with the human leukocyte antigen haplotypes in different major histocompatibility complex class I molecules, using a bioinformatics prediction method to synthesize the antigenic peptide, the antigenic peptide comprising at least one of the amino acid sequences shown in the following table.

[0010]

[0011]

[0012]

[0013]

[0014]

[0015] Preferably, the hepatitis B virus encoded protein includes at least one of HBV_env, HBV_polymerase, HBV_C or HBV_X.

[0016] Preferably, the human leukocyte antigen typing includes at least one of HLA-A*02:01, HLA-A*02:03, HLA-A*02:06, HLA-A*03:01, HLA-A*11:01, HLA-A*24:02, HLA-A*30:01, HLA-A*31:01, HLA-A*32:01, HLA-A*68:01, HLA-B*07:02, HLA-B*40:01, HLA-B*40:02, HLA-B*54:01, HLA-B*58:01, HLA-C*12:03, HLA-C*14:02 or HLA-C*15:02.

[0017] The second aspect of the present invention is to provide a use of the antigen peptide as described above in the preparation of an immunotherapy drug for liver cancer infected by hepatitis B virus.

[0018] Preferably, the immunotherapy drug comprises at least one of an antigen peptide cell therapy drug or a vaccine.

[0019] The present invention adopts the above technical solution, and has the following technical effects compared with the prior art:

[0020] The antigen peptide of the present invention has been verified for its individualized effectiveness by using immune experiments in human experiments, thus filling the gap of individualized antigen peptides in the treatment of liver cancer; the antigen peptide of the present invention can significantly activate the human body's T cells specific to HBV, increase the killing ability of T cells against HBV-infected liver cancer cells, and large-scale synthesis can be used for standardized individualized HBV-related liver cancer immunotherapy. BRIEF DESCRIPTION OF THE DRAWINGS

[0021] Figure 1 Dendritic cells were loaded with antigen peptide 6 and antigen peptide 115. After stimulating and activating T cells, the in vitro reactivity of T cells from liver cancer patient 1 to antigen peptide 6 and antigen peptide 115 was analyzed by IFN-γ ELISPOT assay; positive control: plant lectin PHA; negative control: no peptide added.

[0022] Figure 2 Dendritic cells were loaded with antigen peptide 6 and antigen peptide 23. After stimulating and activating T cells, the in vitro reactivity of T cells from liver cancer patient 2 to antigen peptide 6 and antigen peptide 23 was analyzed by IFN-γ ELISPOT assay; positive control: phytohemagglutinin PHA; negative control: no peptide added.

[0023] Figure 3 Dendritic cells were loaded with antigen peptide 3 and antigen peptide 84. After stimulating and activating T cells, the in vitro reactivity of T cells from liver cancer patient 3 to antigen peptide 3 and antigen peptide 84 was analyzed by IFN-γ ELISPOT assay; positive control: plant lectin PHA; negative control: no peptide added.

[0024] Figure 4 Dendritic cells were loaded with antigen peptide 79 and antigen peptide 115. After stimulating and activating T cells, the in vitro reactivity of T cells from liver cancer patient 4 to antigen peptide 79 and antigen peptide 115 was analyzed by IFN-γ ELISPOT assay; positive control: plant lectin PHA; negative control: no peptide added.

[0025] Figure 5 Dendritic cells were loaded with antigen peptide 6 and antigen peptide 124. After stimulating and activating T cells, the in vitro reactivity of T cells from liver cancer patient 5 to antigen peptide 6 and antigen peptide 124 was analyzed by IFN-γ ELISPOT assay; positive control: plant lectin PHA; negative control: no peptide added. DETAILED DESCRIPTION

[0026] The following will be combined with the drawings in the embodiments of the present invention to clearly and completely describe the technical solutions in the embodiments of the present invention. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.

[0027] It should be noted that, in the absence of conflict, the embodiments of the present invention and the features in the embodiments may be combined with each other.

[0028] The present invention will be further described below in conjunction with the accompanying drawings and specific embodiments, but they are not intended to limit the present invention.

[0029] Example

[0030] 1. Patient HLA typing test

[0031] 2 mL of peripheral blood was drawn from the patient, anticoagulated with EDTA or sodium citrate, and PCR-SBT, Sanger sequencing or second-generation sequencing technology was used to detect the four-digit high-resolution typing of the HLA-A, HLA-B and HLA-C loci of the major histocompatibility complex class I molecules.

[0032] 2. Obtaining PBMC from Peripheral Blood

[0033] (1) COBE Spectra will be used TM The cell bag obtained by the MNC system (or the heparin anticoagulated blood drawn by syringe) is disinfected and placed in the clean bench. The cells are transferred to a 50mL centrifuge tube with a 20mL syringe and diluted with normal saline in a 1:1 ratio.

[0034] (2) Add 20 mL of human lymphocyte separation medium into the centrifuge tube;

[0035] (3) Using a Pasteur pipette, slowly superimpose the cell fluid diluted with physiological saline onto the human lymphocyte separation fluid along the tube wall;

[0036] (4) Horizontal centrifugation at 800 g for 20 min;

[0037] (5) After centrifugation, the tube is divided into three layers: the upper layer is plasma, the lower layer is mainly red blood cells and granulocytes, and the middle layer is lymphocyte separation fluid. At the interface between the upper and middle layers, there is a white film layer mainly composed of mononuclear cells, which is the peripheral blood mononuclear cell layer;

[0038] (6) Use a pipette to insert into the buffy coat layer, aspirate the mononuclear cells, place them into another 50 mL centrifuge tube, add physiological saline, and centrifuge horizontally at 300 g for 10 min.

[0039] (7) Discard the supernatant, add physiological saline, mix well, and centrifuge horizontally at 300g for 10 min;

[0040] (8) Discard the supernatant, add cell culture medium, mix well, and centrifuge horizontally at 300g for 5 min;

[0041] (9) Discard the supernatant, dilute with AIM-V culture medium, count the cells, and take an appropriate amount of cells to freeze as a specimen.

[0042] 3. Dendritic cell (DC) culture:

[0043] (1) According to the above-mentioned PBMC acquisition method, the obtained PBMCs are placed in multiple six-well plate culture bottles and cultured in AIM-V medium;

[0044] (2) Incubate in a 37°C, 5% CO2 incubator for 2 h to allow the monocytes to adhere;

[0045] (3) Isolate adherent cells, add 20 mL of AIM-V medium, supplement with recombinant human GM-CSF (800 U / mL) and recombinant human IL-4 (1000 U / mL), and culture in a 37°C, 5% CO2 incubator to induce monocyte differentiation into DCs;

[0046] (4) On the third day, depending on the cell count, decide whether to change the medium by half. If so, supplement with GM-CSF and IL-4;

[0047] (5) On the sixth day, DC maturation-promoting factors LPS (10 ng / mL) and IFN-γ (100 IU / mL) were added to induce DC maturation for 16-48 h;

[0048] (6) On the seventh day, mature dendritic cells were obtained.

[0049] (7) The mature DCs harvested as described above were added with 10 μg / mL of antigen peptide into the DC culture medium, and incubated in a 37°C, 5% CO2 incubator for 4 to 6 hours. The cells were centrifuged and resuspended in preheated PBS, irradiated with 30 Gy of radiation, and then frozen for later use.

[0050] 4. Enzyme-linked immunosorbent assay (ELISPOT)

[0051] (1) Activate the pre-coated plate by adding 200 μL of AIM-V serum-free medium, leaving it at room temperature for 10 minutes, and pouring it;

[0052] (2) According to the designed grouping, T cells and peptides were added at 10-50 μg / mL, with three replicates in each group;

[0053] (3) After adding all samples, cover the plate, mark it, and place it in a 37°C, 5% CO2 incubator for 20 hours.

[0054] (4) Pour the cells and culture medium in the well;

[0055] (5) Cell lysis: Add 200 μL of ice-cold deionized water to each well and place in a 4°C refrigerator for 10 min (hypotonic cell lysis);

[0056] (6) Washing: Wash each well six times with 260 μL 1× Washing buffer for 60 seconds each time. Dry on absorbent paper after each wash.

[0057] (7) Detection antibody incubation: Add 100 μL of diluted biotin-labeled antibody to each well and incubate at 37°C, 5% CO2 incubator for 1 hour;

[0058] (8) Washing: Wash each well six times with 260 μL 1× Washing buffer for 60 seconds each time. Dry on absorbent paper after each wash.

[0059] (9) Avidin incubation: Add 100 μL of diluted enzyme-labeled avidin to each well and incubate at 37°C for 1 hour;

[0060] (10) Washing: Wash each well six times with 260 μL 1× Washing buffer for 60 seconds each time. Dry on absorbent paper after each wash.

[0061] (11) Color development: Prepare AEC color development solution according to the reagent preparation instructions, add 100 μL of color development solution to each well, and incubate at 37°C, 5% CO2 for color development, checking every 5 minutes;

[0062] (12) After the spots grow to a suitable size, wash twice with deionized water to terminate the color development process. Place the plate upside down on absorbent paper and pat dry the tiny water droplets. Then remove the protective layer and place it in a ventilated place at room temperature to allow the membrane to dry naturally.

[0063] (13) Count the spots on the ELISPOT plate and record various parameters of the spots for analysis.

[0064] 5. Flow cytometry to measure markers of T cell activation

[0065] (1) Adjust the concentration of activated PBMCs or T lymphocytes to 1×10 6 / mL. After the cell suspension is evenly blown, centrifuge at 1500rpm for 5min, discard the supernatant, add PBS, centrifuge at 1500rpm for 5min, discard the supernatant, and resuspend the cells in 100μL PBS into the flow tube, and mark each group of cells on the tube wall;

[0066] (2) Add fluorescent antibodies such as anti-human CD8 and CD137 to label cells, and set up a negative control group, a single-label group, and an isotype control group;

[0067] (3) Stain at 4°C in the dark for 30 min;

[0068] (4) Add 1 mL of PBS and mix gently by pipetting;

[0069] (5) Centrifugation, 1500 rpm, 5 min, discard the supernatant;

[0070] (6) Add 100 μL PBS to resuspend the cells and test on the flow cytometer. BD software was used to collect data and Flowjo software was used to analyze the flow cytometry results.

[0071] 6. In vitro PBMC activation

[0072] (1) From heparinized anticoagulated blood, PBMCs were isolated by the above method and suspended in AIM-V medium (Gibico, USA) and counted.

[0073] (2) Use a 96-well plate with a U-shaped bottom and add 1 × 10 5 PBMCs were diluted in 200 μL culture medium and incubated with 10 μM antigen peptide. The U-shaped bottom is used to promote better contact between cells. The culture medium consists of AIM-V medium (Gibco) containing a small amount of interleukin-2 (IL-2, 100 U / mL, Peprotech) and 10% fetal calf serum (FCS, Gibco).

[0074] (3) PBMCs were cultured for 3 days in each round of stimulation, and the medium was replaced by half once, and the corresponding antigen peptide (10uM) and IL-2 (100U / mL) were supplemented.

[0075] (4) After 2-3 cycles of peptide in vitro stimulation, fresh culture medium was replaced and 10 μM of antigenic peptide was added again for overnight stimulation. Within 24 hours of the next day after the last round of stimulation (i.e., on the 7th and / or 10th day of culture), the expression of IFN-γ was detected by ELISPOT to evaluate the level of T cell immune response and identify the immunogenicity of different antigenic peptides. PBMCs stimulated with no peptide (culture medium) or irrelevant peptides were used as negative controls (NS), and stimulation with plant lectin (PHA) was used as a positive control.

[0076] 7. Use dendritic cells (DC) loaded with antigen peptides to stimulate the activation of mature T cells (1×10 4 / 100 μL / well) in a 37 ° C, 5% CO2 incubator, loaded with peptide 10 μM pulse for 4-6 hours, washed with preheated PBS, and then incubated with T cells overnight in complete AIM-V medium at a 1:10 stimulator to effector ratio. The activation level of T cells was evaluated the next day. The number and intensity of activated T cells after stimulation culture were detected by INF-γELISPOT, and the expression level of T cell activation marker 4-1BB (CD137) was evaluated by flow cytometry.

[0077] 8. Preparation of Neoantigen Reactive T Cells (NRT)

[0078] (1) Transfer the suspended cells to the F225 culture flask and adjust the cell concentration to 1×10 7 / mL, supplemented with IL-2 (100 U / mL), IL-7 (10 ng / mL), and IL-15 (10 ng / mL), and cultured in a 37°C, 5% CO2 incubator for 7 days;

[0079] (2) On the 7th day, mature DCs were harvested, 25 μg / mL of antigen peptide was added to the DC culture medium, and the cells were incubated in a 37°C, 5% CO2 incubator for 4 to 6 hours;

[0080] (3) Centrifuge at 1500 rpm for 5 min, discard the supernatant, mix the DC loaded with the neoantigen with the suspension cells, and add some fresh culture medium containing (IL-2, IL-7, IL-15). Incubate at 37°C, 5% CO2 for 10 days;

[0081] (4) Depending on the cell growth and culture medium color, add half the amount of fresh complete culture medium and corresponding cytokines IL-7, IL-15, and IL-2 every 2 to 3 days and transfer the culture medium to another bottle; depending on the T cell proliferation, add an appropriate amount of OKT3 monoclonal antibody, and add irradiated ECCE cells or APC-loaded peptide prepared from resuscitated frozen PBMC for a second round of stimulation;

[0082] (5) About 10 days after T cells are stimulated with antigens, they are harvested for testing and functional experiments.

[0083] Experimental results analysis:

[0084] like Figure 1-5As shown, patients 1, 2, and 5 have the same HLA-A*02:01 haplotype, so strong immune reactivity was also generated when the same peptide 6 was used; peptide 23 is specific to the HLA-A*02:03 haplotype in patient 2, and also produces a personalized immune response; similarly, peptide 115 can produce immune responses to HLA-C*14:02 in both patients 1 and 4; and peptide 84 and peptide 79 produce immune responses to HLA-C*30:01 in patient 3 and HLA-A*11:01 in patient 4, respectively; in addition, patients 1 and 3 both carry the HLA-A*02:01 haplotype, and peptide 6 and peptide 3 can produce immune responses. This shows that different patients with the same HLA haplotype can produce immune responses to the same or multiple peptides, and also shows that different patients have personalized antigen peptides suitable for their respective HLA haplotypes.

[0085] In summary, the antigen peptides of the present invention have been verified for their individualized effectiveness by using immune experiments in human experiments, thus filling the gap in individualized antigen peptides in the treatment of liver cancer; the antigen peptides of the present invention can significantly activate the human body's T cells specific to HBV, increase the killing ability of T cells against HBV-infected liver cancer cells, and large-scale synthesis can be used in standardized individualized liver cancer immunotherapy.

[0086] The above description is only a preferred embodiment of the present invention, and does not limit the implementation mode and protection scope of the present invention. For those skilled in the art, it should be aware that all solutions obtained by equivalent substitutions and obvious changes made using the description and illustrations of the present invention should be included in the protection scope of the present invention.

Claims

1. Antigenic peptides against hepatitis B virus, Features: The amino acid sequence of the antigenic peptide is as shown in SEQ ID NO:

23.

2. The antigen peptide according to claim 1, It is characterized in that The polypeptide combination further comprises an antigenic peptide as shown in at least one of SEQ ID NO:3, SEQ ID NO:6, SEQ ID NO:79, SEQ ID NO:84, SEQ ID NO:115, and SEQ ID NO:

124.

3. The antigen peptide according to claim 1, It is characterized in that An antigenic peptide polypeptide combination comprising at least two of the amino acid sequences of SEQ ID NOs: 1 to 124 and an amino acid sequence of SEQ ID NO: 23; The polypeptide combination must also meet the requirement that it does not contain the polypeptide combination described in claim 2.

4. Use of the antigen peptide according to any one of claims 1 to 3 in the preparation of an immunotherapeutic drug for liver cancer infected by hepatitis B virus.

5. The use according to claim 4, It is characterized in that The immunotherapy drug includes at least one of an antigen peptide cell therapy drug or a vaccine.

6. The use according to claim 4, It is characterized in that The liver cancer infected by the hepatitis B virus is a liver cancer carrying the HLA-A*02:03 haplotype.